Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polypeptide N-acetylgalactosaminyltransferase 15 (GALNT15) is an enzyme that catalyzes the initial step in O-linked oligosaccharide biosynthesis by transferring an N-acetyl-D-galactosamine residue from UDP-GalNAc to serine or threonine residues on polypeptide substrates. It shows broader substrate specificity toward mucin peptides, such as Muc1a and Muc5AC, but has lower transferase activity compared to related family members. GALNT15 is part of the large family of polypeptide N-acetylgalactosaminyltransferases that regulate mucin-type O-glycosylation—a modification important in extracellular matrix structure, cell signaling, and protein stability. Mutations or dysregulation may be associated with certain diseases, including classic Ehlers-Danlos syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polypeptide N-acetylgalactosaminyltransferase 15 (GALNT15).